Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 387

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 387
---
 | ​ |    -452 | ​ | ​ |
| Other income, net                            | ​ | ​ |                                  ​ | ​ | -12,659 | ​ | ​ | ​ |    ​ | ​ |      — | ​ | ​ | ​ |                                ​ | ​ | -7,159 | ​ | ​ | ​ |    ​ | ​ |       — | ​ | ​ |
| Net income (loss)                            | ​ | ​ |                                  ​ | $ |   4,167 | ​ | ​ | ​ |    ​ | $ | -6,975 | ​ | ​ | ​ |                                ​ | $ | -5,412 | ​ | ​ | ​ |    ​ | $ | -11,177 | ​ | ​ |
| ​                                            |   |   |                                    |   |         |   |   |   |      |   |        |   |   |   |                                  |   |        |   |   |   |      |   |         |   |   |

(1) Pre-clinical, CMC, and other (unallocated) costs include pre-clinical testing, CMC, and other direct research and development expenses that are not allocated to a specific program. (2) Consultant fees and other costs include expenses incurred for research and development consultants as well as payroll costs for employees within the research and development function. (3) Other general and administrative expenses include professional fees, accounting services, rent, and other overhead and administrative expenses. Assets provided to the CODM are consistent with those reported on the condensed consolidated balance sheets. 17. Related-party Transactions During the three and six months ended June 30, 2025 and 2024, the Company did not have any transactions with related parties. The Company evaluates transactions with counterparties who may be considered related parties, including owners, members of management or affiliates and then discloses the nature and amounts of those transactions in the notes to its condensed consolidated financial statements. 18. Subsequent Event On July 4, 2025, President Trump signed H.R.1, the One Big Beautiful Bill Act (OBBBA), into law. OBBBA introduced significant changes to the U.S. federal corporate tax system, including retroactive relief for certain small business taxpayers, such as the reinstatement of immediate expensing for domestic research and developmental expenditures and modifications to the business interest expense limitation. However, since OBBBA was enacted after the June 30, 2025 condensed consolidated balance sheet